Allos Therapeutics, Inc. – Trademark Portfolio
Entity Type: 03
Allos Therapeutics, Inc. holds 23 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 22 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include ALLOS, FOLOTYN, and FOLOTYN (PRALATREXATE INJECTION). The owner is based in Westminster, CO.
11080 Circle Point Road, Suite 200
Westminster, CO 80020
Showing of trademarks Trademarks
Trademark Classifications
Allos Therapeutics, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Allos Therapeutics, Inc. have?
Allos Therapeutics, Inc. has 23 U.S. trademarks filed with the USPTO. Of these, 4 registered, 11 abandoned, 8 cancelled.
What trademark classes does Allos Therapeutics, Inc. file in?
Allos Therapeutics, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Allos Therapeutics, Inc.'s most well-known trademarks?
Allos Therapeutics, Inc.'s registered trademark portfolio includes well-known marks such as ALLOS, FOLOTYN, and FOLOTYN (PRALATREXATE INJECTION). These are among 4 currently registered trademarks in the portfolio.
What is Allos Therapeutics, Inc.'s trademark registration success rate?
Allos Therapeutics, Inc. has a 17% trademark registration rate, with 4 out of 23 resolved applications resulting in successful registration. Currently, 0 applications are pending review.